Birhan maternal and child health cohort: A study protocol

Introduction Reliable estimates on maternal and child morbidity and mortality are essential for health programmes and policies. Data are needed in populations, which have the highest burden of disease but also have the least evidence and research, to design and evaluate health interventions to prevent illnesses and deaths that occur worldwide each year. Methods and analysis The Birhan Maternal and Child Health cohort is an open prospective pregnancy and birth cohort nested within the Birhan Health and Demographic Surveillance System. An estimated 2500 pregnant women are enrolled each year and followed through pregnancy, birth and the postpartum period. Newborns are followed through 2 years of life to assess growth and development. Baseline medical data, signs and symptoms, laboratory test results, anthropometrics and pregnancy and birth outcomes (stillbirth, preterm birth, low birth weight) are collected from both home and health facility visits. We will calculate the period prevalence and incidence of primary morbidity and mortality outcomes. Ethics and dissemination The cohort has received ethical approval. Findings will be disseminated at scientific conferences, peer-reviewed journals and to relevant stakeholders including the Ministry of Health. The Birhan MCH cohort is an open prospective pregnancy and birth cohort nested within the Birhan Health and Demographic Surveillance System (HDSS). Briefly, the Birhan HDSS includes 16 kebeles (lowest administrative unit) in two districts in Amhara, Ethiopia. As of July 2019, the HDSS includes a total of 18 933 households and 77 766 people.15 The site includes eight health facilities (three hospitals and five health centres), where all health services for pregnant women, postpartum women and children under-5 are provided free of charge by the Ministry of Health. The Birhan MCH cohort started in December 2018 and will continue through 2024 with plans to continue as funding allows. Basic health and demographic data are collected every three months through house-to-house surveillance. During these quarterly visits, data collectors conduct pregnancy surveillance among married women of childbearing age through a series of pregnancy screening questions. For women who screen positive, pregnancies are confirmed with urine HCG tests. Non-married women are not screened for pregnancy to respect cultural norms; non-married women who are visibly pregnant may be consented. Pregnant women who consent to participate are enrolled into the MCH cohort. Mothers of and children under -2 are also consented and enrolled into the MCH cohort. Both clinical and epidemiological data are collected at health facilities during antenatal, postnatal and outpatient sick visits and in the community during scheduled home visits. Pregnant women, mothers of children under-2 years of age and children under-2 from the Birhan catchment population are eligible for enrolment if they meet the following inclusion criteria: Women and children are excluded from the study if they are from: Once enrolled, pregnant women are followed both at home and at the health facility. Home visits are conducted every three months until 32 weeks of gestation, then every two weeks. After 36 weeks, home visits alternate with phone visits every week until birth. Postpartum women are followed from birth to 42 days post partum with scheduled home visits on days 0 (birth), 6, 28 and 42 after birth. Newborns and children under-2 years are followed on days 0 (birth), 6, 28 and 42 and months 6, 12 and 24. Participants who present to health facilities for antenatal care, postnatal visits or sick visits (outpatient or admission) also have data collected by study data collectors at the health facility. Participants are censored from the study with the following events: out-migration from the catchment area, death, lost to follow-up and at the end of the follow-up period (figure 1). In addition, all participants (including pregnant women, postpartum women and children under-2) are concurrently followed on a quarterly basis by the underlying HDSS, which includes basic health questionnaires and an under-2 year old questionnaire on child morbidity. Schedule of study enrolment and follow-up visits Antenatal care visit. Postpartum care visit. Neonatal /child visit. Time window for scheduled visits. Time window for unscheduled visits. OPD; Outpatient Department. Data are collected by several sources: maternal or caretaker recall, data collector assessments in the community, health worker observations at the community, health centre and hospital level. Data collected at the time of HDSS enrolment include household data on socioeconomic status, drinking water and sanitation access, flooring/wall/roof materials, number of rooms used for sleeping, place of cooking, household possessions and ownership of land. Individual (mother, father, child and grandparent) specific data on education, employment, literacy, religion, care seeking behaviours and immunisation rates are collected. Anthropometric data including weight, height and mid-upper arm circumference (MUAC) measurements are collected for women of childbearing age and children under-2 following standardised procedures and equipment: Seca 874 digital flat scale, Seca 354 digital baby scale, Seca 417 infantometers and tape measures. Data collectors were recruited from the local villages with at least a diploma in clinical nursing or midwifery. Supervisors have at least a master’s in public health. For study purposes, data collectors received four weeks of intensive training with lectures, interactive discussions on the study protocol coupled with practical training sessions on clinical assessments and anthropometric measurements. Following training, there is onsite supervision and mentorship every week. Pregnant women enrolled into the cohort receive an ultrasound for gestational age dating at their earliest antenatal care (ANC) visit. Information on the pregnancy (birth spacing, antenatal care visits) and pregnancy-related symptoms, including history of vaginal bleeding, dysuria, headache, fever, abdominal pain and fetal movement are collected. Maternal weight and observations of clinical signs such as pallor, jaundice and oedema are collected. For newborns enrolled in the cohort, data on labour and delivery (location of delivery, delivery method, duration of labour, complications of birth, birth weight) and immediate newborn care (breast feeding, cord-care, bathing, skin emollients) are collected as soon as possible with a target of within 24 hours of birth. Mothers or caretakers recall of clinical symptoms, observations of signs of illness and newborn weight are collected at subsequent postpartum visits. Sick visits include outpatient clinic visits and hospital admissions. Clinical symptoms, observations of signs of illness and possible risk factors such as sick contacts, food sources, travel and water sanitation and hygiene practices are collected at sick visits. Additionally, data on treatment modalities, referrals and vital status are collected at discharge. To ascertain the cause of death, verbal autopsies (VAs) are conducted to obtain information on the symptoms, signs and other relevant events during the illness leading to death. Three VA questionnaires (for deaths 0–28 completed days of life; deaths of children between four weeks and 11 years of age; and deaths of persons aged 12 years and above which includes pregnancy-related questions for women of reproductive age) adopted from the standard 2016 WHO VA questionnaires are used.16 Verbal autopies were developed to provide information on causes of death in communities where there is limited access to healthcare and medical certification of causes of death. In such situations, the main source of information about the event is from caregivers of the deceased, most often family members. Ascertaining causes of death from such information is based on the premise that VA respondents can accurately recall details of the symptoms and events that occurred during the period of illness prior to death, and that such information can be used to classify the cause(s) of death into diagnostic categories based on specific symptoms. We use the Birhan electronic data collection system, built from Open Data Kit (ODK),17 for longitudinal and relational data collection. ODK is a free, open-source application used to facilitate mobile data capture. ODK can be coded using SQL to facilitate data collection, transfer and storage, as well as the development of electronic questionnaires used for data collection. Data can be collected on a mobile device offline. Data are uploaded daily using mobile data to a central database. Data quality checks are built into the data entry tools and data system. Data are hosted on an encrypted central database on the cloud and are deidentified. The data system is developed and maintained by two data system developers. Data are managed by a team of data scientists and data managers in Stata (V.17.0) and R/RStudio (V.4.0.5).18 19 To ensure high data quality, we developed simple user-friendly questionnaires which were piloted prior to use. We recruited and trained data collectors who met a minimum level of competency as described above and through pre–post training examinations. Supervisors oversee study implementation by supporting data collectors with weekly on-the site mentorship and weekly team meetings. Supervisors independently conduct home visits on a 5% random sample of households to validate data collector performance. Within the electronic data capture system, we built single field value checks, interfield logic checks and interform logic checks. In case of an error at the time of data entry, pop-up warnings are triggered, prompting the user to resolve any issues prior to saving the record. Following data collection, the dataset is systematically checked for data quality issues by a team of analysts. Data quality issues are recorded, provided to data collectors to identify solutions and then rectified in the dataset. Primary outcomes include: Secondary outcomes include recurrence of illnesses; readmissions and growth as measured by weight, height, MUAC and body mass index; maternal and child immunisations, and exclusive breast feeding. For each of the primary outcomes, we will calculate the period prevalence and incidence at community and health facilities levels. To estimate period prevalence, we will sum the 2-week periods over all the participants within certain age ranges as the denominator and sum the number of episodes within that 2-week period as the numerator (i.e., cases over sum of person-days observed or person-days recalled). We will estimate the incidence for each outcome by taking the sum of all the person-time contributed by each person as the denominator, and the sum of all episodes over the study period as the numerator. Missing data will be assessed through quality assurance checks by field supervisors and rectified through a documented error correction system. Remaining incomplete data will be addressed through analytical approaches. We will repeat the above analyses with varying case definitions of disease severity. In a population of 77 000, we expect approximately 2500 pregnancies per year and 4500 children under-2 years of age. Using historical data and the literature, we expect a range of outcome rates from 2.0% to 20.0% depending on outcome of interest (table 1). The prevalence of stillbirths is estimated to be 9.2 per 1000 births in Ethiopia and 19.7 per 1000 births (around 2.0%) in Amhara.24 The prevalence of diarrhoea over a 2-week period among children under-2 varies by region: 31.3%25 in Afar, 18.5% in Southern Nations, Nationalities, and People’s Region (SNNPR), 16.0% in Oromia, 17.7% in Amhara and 6.8% in Tigray.26 Given this variation, we estimate the prevalence of diarrhoea over a 2-week period among children under-2 to be 20.0%. We expect the prevalence of acute respiratory infection over a 2-week period among children under-2 to be 5.0% based on preliminary data in Ethiopia.26 Outcomes of interest, estimated prevalence and precision (95% CI width) by sample size* *Precision calculated using exact distribution for <5% prevalence and Wald distribution for ≥5% prevalence. †Estimated 2-week point prevalence for children under 2 years old. To estimate absolute precision (defined as the half-width of the 95% CI) for outcomes ranging in prevalence from 2.0% to 20.0%, the exact (Clopper-Pearson) distribution was used for rare outcomes (<5%) and the Wald distribution was used for common outcomes (>5%).27 28 A sample size of 2500 pregnant women would estimate the prevalence for a rare outcome such as stillbirth, 2.0%, with 0.6% precision (95% CI 1.4% to 2.6%) (table 1). For more common outcomes such as preterm birth, a sample size of 2500 pregnant women would estimate a 12.0% prevalence with 1.3% precision (95% CI 10.7% to 13.3%). A sample size of 4500 children would estimate a 20.0% prevalence of diarrhoea with 1.2% precision (95% CI 18.8% to 21.2%). A sample size of 4500 children would estimate a 5.0% prevalence of ARI with 0.5% precision (95% CI 4.5% to 5.5%). Period prevalence will vary based on case definitions and severity of illnesses. To examine risk factors and correlates for these outcomes, we will conduct tests of association to detect statistically significant effect sizes for risk factors and outcomes assessed in this study.